These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9507813)

  • 1. Impacts of blood screening on the incidence of posttransfusion hepatitis C in Japan.
    Yoshizawa H; Watanabe J
    Curr Stud Hematol Blood Transfus; 1998; (62):237-49. PubMed ID: 9507813
    [No Abstract]   [Full Text] [Related]  

  • 2. Impacts of blood screening on the incidence of posttransfusion hepatitis C in Japan.
    Yoshizawa H; Watanabe J
    Curr Stud Hematol Blood Transfus; 1994; (61):182-94. PubMed ID: 7525155
    [No Abstract]   [Full Text] [Related]  

  • 3. [Donors blood screening and prevention of posttransfusion type C hepatitis in Japan].
    Yoshizawa H
    Uirusu; 1993 Dec; 43(2):315-21. PubMed ID: 7510090
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatitis C virus infection in Japan.
    Nishioka K
    Gastroenterol Jpn; 1991 Jul; 26 Suppl 3():152-5. PubMed ID: 1909256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Demonstrating antibodies against hepatitis C virus in transfusion practice. Viral Hepatitis Working Group of the Société Française de la Transfusion Sanguine].
    Maisonneuve P; Noël L
    Transfus Clin Biol; 1994; 1(5):397-400. PubMed ID: 7529098
    [No Abstract]   [Full Text] [Related]  

  • 6. Prospective assessment of donor blood screening for antibody to hepatitis C virus and high-titer antibody to hepatitis B core antigen as a means of preventing post-transfusion hepatitis.
    Takano S; Omata M; Ohto M; Nakamura K
    Gastroenterol Jpn; 1993 May; 28 Suppl 5():84-7. PubMed ID: 7689514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The efficacy of excluding anti-HVC-positive donors by ELISA 2 in the prevention of posttransfusion hepatitis].
    Barrera JM; Bruguera M; González M; Gálvez A; Castillo R; Rodés J
    Gastroenterol Hepatol; 1996 May; 19(5):240-2. PubMed ID: 8752564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of screening and complementary tests for anti-HCV antibodies].
    Głoskowska-Moraczewska Z; Kacperska E; Seyfried H
    Acta Haematol Pol; 1993; 24(3):273-80. PubMed ID: 7504386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HCV and blood transfusion.
    Reesink HW; van der Poel CL; Cuypers HT; Lelie PN
    Arch Virol Suppl; 1992; 4():241-3. PubMed ID: 1280507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Declared hepatitis C screening strategies in blood recipients in French hospitals.
    Jusot JF; Aubert C; des Floris MF; Rotily M; Lançon F; Colin C; Jullien AM; Fournel JJ; Laubriat L; Fabre G; Botté C; Montcharmont P
    Transfus Clin Biol; 2002 Apr; 9(2):130-6. PubMed ID: 12058556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of transmission of hepatitis B, hepatitis C and human immunodeficiency virus infections through blood transfusion by anti-HBc testing.
    Busch MP
    Vox Sang; 1998; 74 Suppl 2():147-54. PubMed ID: 9704438
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of screening blood donors for hepatitis C antibody on posttransfusion hepatitis: a prospective study with a second-generation anti-hepatitis C virus assay.
    Huang YY; Yang SS; Wu CH; Shih WS; Huang CS; Chen PH; Lin YM; Shen CT; Chen DS
    Transfusion; 1994 Aug; 34(8):661-5. PubMed ID: 7521077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posttransfusion hepatitis in Japan.
    Takano S; Omata M; Ohto M; Satomura Y
    Vox Sang; 1992; 62(3):156-64. PubMed ID: 1609517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hepatitis C antibody screening in blood donors on post-transfusion hepatitis in Taiwan.
    Wang JT; Wang TH; Lin JT; Lee CZ; Sheu JC; Chen DS
    J Gastroenterol Hepatol; 1995; 10(4):454-8. PubMed ID: 8527713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of post-transfusion hepatitis before and after screening for hepatitis C virus antibody.
    Wang YJ; Lee SD; Hwang SJ; Chan CY; Chow MP; Lai ST; Lo KJ
    Vox Sang; 1994; 67(2):187-90. PubMed ID: 7528456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Look-back screening for the identification of transfusion-induced hepatitis C virus infection in Sweden.
    Ydreborg M; Söderström A; Håkanson A; Alsiö A; Arnholm B; Malmström P; Hellstrand K; Westin J; Lagging M
    Scand J Infect Dis; 2011 Jul; 43(6-7):522-7. PubMed ID: 21375426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective assessment of donor blood screening for antibody to hepatitis C virus by first- and second-generation assays as a means of preventing posttransfusion hepatitis.
    Takano S; Nakamura K; Kawai S; Yokosuka O; Satomura Y; Omata M
    Hepatology; 1996 Apr; 23(4):708-12. PubMed ID: 8666321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions.
    Bruhn R; Lelie N; Busch M; Kleinman S;
    Transfusion; 2015 Jun; 55(6):1195-205. PubMed ID: 25727549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective assessment of incidence of fulminant hepatitis in post-transfusion hepatitis: a study of 504 cases.
    Takano S; Omata M; Ohto M; Satomura Y
    Dig Dis Sci; 1994 Jan; 39(1):28-32. PubMed ID: 7506644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus: Prevention, screening, and interpretation of assays.
    Albeldawi M; Ruiz-Rodriguez E; Carey WD
    Cleve Clin J Med; 2010 Sep; 77(9):616-26. PubMed ID: 20810872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.